Lacosamide Brand names: Vimpat, Motpoly

What is lacosamide used for?

From the label: indications and usage

VIMPAT is indicated for: Treatment of partial-onset seizures in patients 1 month of age and older ( 1.1 ) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older ( 1.2 ) 1.1 Partial-Onset Seizures VIMPAT is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. 1.2 Primary Generalized Tonic-Clonic Seizures VIMPAT is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.

Conditions named in the indications of lacosamide's FDA labels, with every medicine labeled for each:

• Seizures and epilepsy

What does the patient leaflet for lacosamide say first?

The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.

From the patient leaflet: What is the most important information I should know about VIMPAT?

Do not stop taking VIMPAT without first talking to your healthcare provider. Stopping VIMPAT suddenly can cause serious problems. Stopping seizure medicine suddenly in a patient who has epilepsy can cause seizures that will not stop (status epilepticus). VIMPAT can cause serious side effects, including: Like other antiepileptic drugs, VIMPAT may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying attempt to commit suicide new or worse depression new or worse anxiety feeling agitated or restless panic attacks trouble sleeping (insomnia) new or worse irritability acting aggressive, being angry, or violent acting on dangerous impulses an extreme increase in activity and talking (mania) other unusual changes in behavior or mood How can I watch for early symptoms of suicidal thoughts and actions? Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you are worried about symptoms. Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes. VIMPAT may cause you to feel dizzy, have double vision, feel sleepy, or have problems with coordination and walking. Do not drive, operate heavy machinery, or do other dangerous activities until you know how VIMPAT affects you. VIMPAT may cause you to have an irregular heartbeat or may cause you to faint. In rare cases, cardiac arrest has been reported. […]

From the patient leaflet: What should I avoid while taking VIMPAT?

Do not drive, operate heavy machinery, or do other dangerous activities until you know how VIMPAT affects you. VIMPAT may cause you to feel dizzy, have double vision, feel sleepy, or have problems with coordination and walking.

From the patient leaflet: How should I store VIMPAT?

Store VIMPAT at room temperature between 68ºF to 77ºF (20ºC to 25ºC). Do not freeze VIMPAT injection or oral solution. Throw away any unused VIMPAT oral solution 6 months after you first open the bottle. Keep VIMPAT and all medicines out of the reach of children. General Information about the safe and effective use of VIMPAT . Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use VIMPAT for a condition for which it was not prescribed. Do not give VIMPAT to other people, even if they have the same symptoms that you have. It may harm them. This Medication Guide summarizes the most important information about VIMPAT. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about VIMPAT that is written for health professionals.

Is there a generic for lacosamide (Vimpat)?

The FDA approved the first generic lacosamide on March 17, 2022. 44 generic applications are approved; 36 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale. Drugs@FDA also holds 2 tentative approvals: the FDA found the generic approvable, but patents or exclusivity keep it from final approval for now.

FDA's NDC Directory lists lacosamide from 57 labelers under a generic (ANDA) application and from 2 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.

The Orange Book lists no patent for Vimpat tablets; a patent listed only for Motpoly XR capsules runs to June 5, 2040. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.

What do pharmacies pay for lacosamide (Vimpat)?

In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.174 per Lacosamide 100 mg tablet, down 15% from $0.206 on October 8, 2025. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.

Has lacosamide been recalled?

The FDA's Enforcement Report lists 8 recalls naming lacosamide since 2021: 0 Class I (the most serious), 7 Class II, 1 Class III; 6 still ongoing. A recall names products and lots, not every product of the medicine.

What does the lacosamide label say about other medicines?

The lacosamide label names no other medicine on this site. The labels of 2 other medicines name lacosamide. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.

Check lacosamide against other medicines

What do FAERS reports show for lacosamide?

The FDA Adverse Event Reporting System holds 36,995 reports that list lacosamide among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 3,133 are coded as a death and 12,683 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

Reports received each year

• 1,342
• 1,652
• 2,469
• 3,766
• 2,936
• 3,545
• 3,208
• 3,139
• 3,497
• 3,308
• 1,547

• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

The most reported reactions

• Seizure (a use or a product term, not a reaction)6,858
• Drug Ineffective (a use or a product term, not a reaction)4,137
• Off Label Use (a use or a product term, not a reaction)3,974
• Dizziness (named in the label)1,669
• Somnolence (named in the label)1,497
• Fatigue (named in the label)1,446
• Epilepsy (named in the label)1,417
• Fall1,395

Side effects: the label's list and every FAERS reaction

What else is labeled for the same conditions as lacosamide?

18 other medicines are given the same way (oral) and in the same FDA class as lacosamide or labeled mainly for the same use (seizures and epilepsy), the same class first. Seizures and epilepsy lists all 27 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.

Every medicine labeled for the same conditions as lacosamide

How does lacosamide compare with medicines for the same use?

7 side-by-side pages set lacosamide beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.

• Carbamazepine
• Gabapentin
• Lamotrigine
• Levetiracetam
• Oxcarbazepine
• Pregabalin
• Zonisamide

What next?

Alternatives to lacosamide

18 medicines for the same use

Lacosamide side effects

the label's list beside FAERS reports

Check an interaction

what two or more labels say about each other